Fig. 1: Altered CBP/p300 expression correlates with aggressive disease.
From: AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer
A Frequency of AR, CBP, and p300 gene alterations (i.e., amplifications, mutations, and/or deletions) in primary and metastatic PCa datasets from cBioPortal—TCGA Firehose Legacy and SU2C/PCF Dream Team (PNAS 2019) datasets. Hormone sensitive PCa total alterations AR n = 9, CBP n = 12, and p300 n = 7, and castration-resistant PCa AR n = 252, CBP n = 36, and p300 n = 8. B Correlation of CBP and p300 mRNA expression in metastatic PCa patient tumors from SU2C/PCF Dream Team (PNAS 2019) data set from cBioportal. C CBP and p300 are highly expressed in primary PCa (top 10% expressed genes) and mCRPC (top 25% expressed genes) and are associated with poor outcome. D cBioportal analyses for disease-free survival from prostate adenocarcinoma data set (SKCC, Cancer Cell 2010).
